Background: Consensus statements recommend that statin treatment in children with heterozygous familial hypercholesterolemia (FH) should be considered from 8 to 10 years of age. Although these recommendations are well known, less is known about actual treatment and treatment goal attainment in children with FH.
Objective: The objective of the study was to investigate if children with FH were treated according to current recommendations.
Methods: Retrospective collection of data from medical records of 302 children below 18 years visiting the Lipid Clinic, Oslo University hospital, during 2014 to 2016.
Results: Ninety-nine percent had a genetically verified FH diagnosis. Mean age (standard deviation) at diagnosis, age at first visit, and time followed at the clinic was 8.5 (3.2), 9.5 (2.9), and 4.4 (2.7) years, respectively. Mean pretreatment low-density lipoprotein cholesterol (LDL-C) was 5.4 (1.4) mmol/L. Mean age at start of lipid-lowering therapy (LLT) was 12.5 (2.0) years, with no significant difference between girls and boys. LLT, mainly statins, was used by 177 (59%) children at their last visit. LDL-C in children treated with LLT was 3.6 (1.2) mmol/L (38% reduction from pretreatment, P < .001). A treatment goal of LDL-C ≤3.5 mmol/L was achieved by 43% of all children, by 58% of the children on LLT, and by 22% of children not on LLT.
Conclusion: Mean age at initiation of LLT is above the recommended 10 years of age and many children did not achieve the LDL-C treatment goal, even with follow-up at a dedicated lipid clinic. Earlier diagnosis and more frequent follow-ups are warranted.
Keywords: Children; Familial hypercholesterolemia; Genetic testing; LDL cholesterol; Lipid-lowering therapy.
Copyright © 2017 National Lipid Association. Published by Elsevier Inc. All rights reserved.